Founded out of the Stanford laboratory of Steve Quake, Bluestar Genomics develops proprietary, next-generation epigenomic, and big data approaches to obtain comprehensive disease information about a patient -- with a simple and non-invasive sample -- that will be used to solve large healthcare market needs.
this is precision
reinventing liquid biopsy
Non-invasive “liquid biopsy,” using cell-free DNA and high throughput genetic analyses, traditionally focuses on detecting sequence differences. This has limited big data applications to clinical conditions where such differences exist.
With the addition of epigenomics, we escape the limitations of sequence alone, providing new disease and clinical information to solve broader healthcare needs.
Bluestar Genomics applies proprietary chemistries, bioinformatics, and big data approaches to next generation sequencing. We interpret patterns of DNA hydroxymethylation and other epigenomic characteristics to provide new biological and clinical information, going beyond the sequence.
Song et al, Cell Research 2017
Song et al, PNAS 2016
bioRxiv Preprint, 2018
medRxiv Preprint, 2020
Bluestar Genomics Receives FDA Breakthrough Device Designation for First-of-Its-Kind Pancreatic Cancer Screening Test >> Read Press Release
In the first steps toward innovative liquid biopsy applications, Bluestar Genomics reports epigenomics results stratifying pancreatic cancer patients from cell free DNA samples. >> Read Press Release
Stanford Spinout Bluestar Genomics Develops Epigenomic Method to Detect Pancreatic Cancer. >> Read GenomeWeb Article
Aiming to improve early diagnosis of cancer using noninvasive methods, Bluestar Genomics presents data demonstrating the feasibility of a novel blood test for earlier detection and classification of multiple cancers. >> Read Press Release
Bluestar Genomics shares new noninvasive data for earlier cancer detection with promising performance at 11th CNAPs International Symposium. >> Read Press Release
Bluestar Genomics’ Breakthrough Study Highlights Promising Data for Multi-Cancer Detection from a Single Blood Draw. >> Read Press Release
- Cell/Tissue Specificity
Identify changes in specific organs using a systemic sample
- Biological Activity
Detect biological activity and gene expression
- Disease Biomarkers
Reveal the presence and progression of disease
- Drug Development
Improve therapy selection, efficacy and safety monitoring
- Health Monitoring
Assess individual organ systems and biological functions
- Non-Invasive Sampling
Avoid biopsy, surgery or direct tissue requirements
- Systems Biology
Uncover the hidden interactions of multiple systems simultaneously
great chemistry | big data | systems biology
We look for extraordinary lifelong learners with a passion and growth mindset for the above disciplines, and for combining biological ingenuity with AI and data analysis, to improve healthcare outcomes. Led by a team with decades of experience bringing products from concept to market, we have offices in the San Francisco Bay Area and San Diego.